JPH0337526B2 - - Google Patents
Info
- Publication number
- JPH0337526B2 JPH0337526B2 JP57158605A JP15860582A JPH0337526B2 JP H0337526 B2 JPH0337526 B2 JP H0337526B2 JP 57158605 A JP57158605 A JP 57158605A JP 15860582 A JP15860582 A JP 15860582A JP H0337526 B2 JPH0337526 B2 JP H0337526B2
- Authority
- JP
- Japan
- Prior art keywords
- carboxylic acid
- solution
- absorption spectrum
- multiplet
- lactone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 150000002596 lactones Chemical class 0.000 claims description 24
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 7
- 150000003839 salts Chemical class 0.000 claims description 6
- 125000005907 alkyl ester group Chemical group 0.000 claims description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 71
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 66
- -1 alkali metal salt Chemical class 0.000 description 50
- 239000000243 solution Substances 0.000 description 43
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 42
- 238000000862 absorption spectrum Methods 0.000 description 37
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 36
- 150000001875 compounds Chemical class 0.000 description 31
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 21
- 238000000034 method Methods 0.000 description 21
- 230000000704 physical effect Effects 0.000 description 21
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 20
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 20
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 20
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 18
- 239000000284 extract Substances 0.000 description 18
- 238000004519 manufacturing process Methods 0.000 description 18
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 239000000203 mixture Substances 0.000 description 14
- 239000002904 solvent Substances 0.000 description 13
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 12
- 238000000921 elemental analysis Methods 0.000 description 11
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 10
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 10
- 239000000741 silica gel Substances 0.000 description 10
- 229910002027 silica gel Inorganic materials 0.000 description 10
- 239000010409 thin film Substances 0.000 description 10
- 241001061260 Emmelichthys struhsakeri Species 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- 238000001819 mass spectrum Methods 0.000 description 8
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- YXHKONLOYHBTNS-UHFFFAOYSA-N Diazomethane Chemical compound C=[N+]=[N-] YXHKONLOYHBTNS-UHFFFAOYSA-N 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 230000003197 catalytic effect Effects 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 235000017557 sodium bicarbonate Nutrition 0.000 description 5
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 5
- 229910052938 sodium sulfate Inorganic materials 0.000 description 5
- 235000011152 sodium sulphate Nutrition 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- XLYOFNOQVPJJNP-ZSJDYOACSA-N Heavy water Chemical compound [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 4
- 208000031226 Hyperlipidaemia Diseases 0.000 description 4
- 239000001888 Peptone Substances 0.000 description 4
- 108010080698 Peptones Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 229940041514 candida albicans extract Drugs 0.000 description 4
- ULDHMXUKGWMISQ-UHFFFAOYSA-N carvone Chemical compound CC(=C)C1CC=C(C)C(=O)C1 ULDHMXUKGWMISQ-UHFFFAOYSA-N 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000013028 medium composition Substances 0.000 description 4
- AJLFOPYRIVGYMJ-INTXDZFKSA-N mevastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=CCC[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 AJLFOPYRIVGYMJ-INTXDZFKSA-N 0.000 description 4
- 235000019319 peptone Nutrition 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000006884 silylation reaction Methods 0.000 description 4
- 239000008399 tap water Substances 0.000 description 4
- 235000020679 tap water Nutrition 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 239000012138 yeast extract Substances 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- XCOBLONWWXQEBS-KPKJPENVSA-N N,O-bis(trimethylsilyl)trifluoroacetamide Chemical compound C[Si](C)(C)O\C(C(F)(F)F)=N\[Si](C)(C)C XCOBLONWWXQEBS-KPKJPENVSA-N 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 238000005502 peroxidation Methods 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- TVZRAEYQIKYCPH-UHFFFAOYSA-N 3-(trimethylsilyl)propane-1-sulfonic acid Chemical compound C[Si](C)(C)CCCS(O)(=O)=O TVZRAEYQIKYCPH-UHFFFAOYSA-N 0.000 description 2
- 241000293029 Absidia caerulea Species 0.000 description 2
- 239000005973 Carvone Substances 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- 230000007059 acute toxicity Effects 0.000 description 2
- 231100000403 acute toxicity Toxicity 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000029936 alkylation Effects 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- 239000012230 colorless oil Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- CSCPPACGZOOCGX-WFGJKAKNSA-N deuterated acetone Substances [2H]C([2H])([2H])C(=O)C([2H])([2H])[2H] CSCPPACGZOOCGX-WFGJKAKNSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 238000007273 lactonization reaction Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000012521 purified sample Substances 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- LXZBFUBRYYVRQJ-AXHZAXLDSA-M sodium;(3r,5r)-7-[(1s,2s,6r,8s,8ar)-2,6-dimethyl-8-[(2s)-2-methylbutanoyl]oxy-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoate Chemical compound [Na+].C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC([O-])=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@@H](C)C=C21 LXZBFUBRYYVRQJ-AXHZAXLDSA-M 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- ZAPILWYLGCELPB-UHFFFAOYSA-N 1,2,3,4,4a,5-hexahydronaphthalene-1-carboxylic acid Chemical group C1C=CC=C2C(C(=O)O)CCCC21 ZAPILWYLGCELPB-UHFFFAOYSA-N 0.000 description 1
- RZYHXKLKJRGJGP-UHFFFAOYSA-N 2,2,2-trifluoro-n,n-bis(trimethylsilyl)acetamide Chemical compound C[Si](C)(C)N([Si](C)(C)C)C(=O)C(F)(F)F RZYHXKLKJRGJGP-UHFFFAOYSA-N 0.000 description 1
- QLPZEDHKVHQPAD-UHFFFAOYSA-N 2,2,2-trifluoro-n-trimethylsilylacetamide Chemical compound C[Si](C)(C)NC(=O)C(F)(F)F QLPZEDHKVHQPAD-UHFFFAOYSA-N 0.000 description 1
- ZSLUVFAKFWKJRC-IGMARMGPSA-N 232Th Chemical compound [232Th] ZSLUVFAKFWKJRC-IGMARMGPSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241000235395 Mucor Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 229910052776 Thorium Inorganic materials 0.000 description 1
- 241000981595 Zoysia japonica Species 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- TXHIDIHEXDFONW-UHFFFAOYSA-N benzene;propan-2-one Chemical compound CC(C)=O.C1=CC=CC=C1 TXHIDIHEXDFONW-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- BOZILQFLQYBIIY-UHFFFAOYSA-N mevastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CCC=C21 BOZILQFLQYBIIY-UHFFFAOYSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 235000013547 stew Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- RUJLHPZAKCVICY-UHFFFAOYSA-J thorium(4+);disulfate Chemical compound [Th+4].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O RUJLHPZAKCVICY-UHFFFAOYSA-J 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
本発明は、
式
または
(式中、R1は水素原子またはメチル基を示し、
R2は水素原子またはメチル基を示し、R5は水酸
基またはメトキシ基を示す。)を有するカルボン
酸、その薬理上許容しうる塩、その低級アルキル
エステルまたはそのラクトン体を有効成分とする
高血清過酸化脂質血症治療剤に関する。
先にML−236Bが高血清過酸化脂質血症治療剤
として有用なことが知られている(特開昭56−
110618号公報参照)。
本発明者らは今回、前記式()または()
を有する化合物およびその誘導体が高血清過酸化
脂質血症治療に有効であることを見い出した。
本発明において使用される前記式()または
()を有するカルボン酸の誘導体としては、そ
の薬理上許容しうる塩、その低級アルキルエステ
ルまたはそのラクトン体である。
前記式()または()を有するカルボン酸
の薬理上許容しうる塩、例えばトリウム、カリウ
ム等のアルカリ金属塩である。
前記式()または()を有するカルボン酸
の低級アルキルエステルは、例えばメチル、エチ
ル、プロピル、イソプロピル、ブチル、イソブチ
ル等である化合物である。
前記式()または()を有する化合物のラ
クトン体は、ヘキサヒドロナフタリン酸における
8位の置換基が次式の部分構造式を有する化合物
である。
前記式()において、R1が水素原子である
化合物は3−ヒドロキシ−ML−236B類であり、
その3位の置換基が〓OHの化合物をM−4類、
…OHの化合物をM−4′類と略称する。この化合
物は特開昭57−50894号および特願昭56−105967
号明細書にその製法と共に記載されている。
前記式()において、R1がメチル基でる化
合物を以下、3−ヒドロキシ−MB−530B類と
略称する。この化合物は特願昭56−134558号明細
書にその製法と共に記載されている。
前記式()において、R2が水素原子であり、
R3が水酸基である化合物は6−ヒドロキシ−イ
ソML−236B類であり、その6位の置換基が〓
OHの化合物をイソM−4類、…OHの化合物を
イソM−4′類を略称する。この化合物は特願昭56
−195160号、特開昭57−108039号および特開昭57
−50894号明細書にその製法と共に記載されてい
る。
前記式()において、R2が水素原子であり、
R3がメトキシ基である化合物を以下、6−メト
キシ−イソML−236B類と略称する。この化合物
は特願昭56−114038号明細書にその製法と共に記
載されている。
前記式()において、R2がメチル基であり、
R3が水酸基である化合物を以下、6−ヒドロキ
シ−イソMB−530B類と略称する。この化合物
は特願昭56−134558号明細書にその製法と共に記
載されている。
前記式()または()を有する化合物は、
前記MB−530BまたはML−236Bあるいはこれら
の誘導体を原料化合物として、前記特許出願明細
書に記載された方法により、微生物による酵素的
水酸化によつて得られる。
以下に、これらの化合物の製造例を述べる。
製造例1 M−4′類
(1) 下記組成の培地100mlを含有する500ml容三角
フラスコ20本にシンセフアラストラム・ニグリ
カンスSANK42372(微工研菌寄第6043号)を
植菌し、26℃、220r.p.m.で振盪培養し、3日
後、ML−236Bラクトン体を最終濃度で0.05%
になるように添加して更に6日間、26℃、
220r.p.m.で培養した。
培地組成
グルコース 1.0%
ペプトン 0.2
肉エキス 0.1
酵母エキス 0.1
コーンスチーブリカー 0.3
水道水 残
(PH未修正)
培養終了後、変換反応液を過し、液をトリ
フルオロ酢酸でPH3に調整した。次いで、1の
酢酸エチルで3回抽出するとM−4′カルボン酸を
含む区分が得られた。
M−4′カルボン酸の物性値
1 TLC
TLCプレート:メルク社製シリカゲル
Art5715
溶媒;ベンゼン:アセトン:酢酸=50:50:
3
Rf値 0.46
(2) (1)の抽出液を飽和食塩水で洗浄し、硫酸ナト
リウムで脱水後、触媒量のトリフルオロ酢酸を
添加してラクトン化した。次いで、上記抽出液
を5%炭酸水素ナトリウム水溶液で洗浄し、硫
酸ナトリウムで脱水後、減圧乾固した。次い
で、得られた残留物をローバー・カラム(メル
ク社製、Si60サイズA)を用い、ベンゼン:ア
セトン=7:3で溶出してM−4′ラクトン体を
採取し、さらに酢酸エチルを用いて再結晶に付
すとM−4′ラクトン体約180mgが得られた。
M−4′ラクトン体の物性値
1 NMRスペクトル
重クロロホルム中、内部標準にTMSを使用し
て、100MHzで測定した。(CDCl3,δ:ppm)
4.25(1H,多重線)
4.60(1H,多重線)
5.50(1H,多重線)
5.75(1H,多重線)
5.90(1H,四重線)
6.01(1H,二重線)
2 紫外部吸収スペクトル(メタノール溶液)
λmax(nm):230,237,245
3 赤外部吸収スペクトル(KBr法)cm-1:
3500,1720
4 マススペクトル
m/e:406(M+),304,286
5 旋光度
〔α〕D:+310.9゜(C=0.66,メタノール)
6 融点
141〜143℃
7 元素分析値(%) C23H34O6として
理論値 C,67.95;H,8.43
実験値 C,68.05;H,8.37
8 TLC
TLCプレート;メルク社製シリカゲルArt5715
溶媒;ベンゼン:アセトン=1:1
Rf値 0.64
(3) (1)の抽出液を飽和食塩水で洗浄し、次いで5
%炭酸水素ナトリウム水溶液を用いて水層に転
溶することによりM−4′カルボン酸ナトリウム
塩を含む区分が得られた。この水層を0.1N塩
酸でPH8.0調整し、次いでM−4′カルボン酸ナ
トリウム塩を含む区分を、ダイヤイオンHP−
20カラム(三菱化成工業(株)製品)に吸着させ
た。50%アセトンでM−4′カルボン酸ナトリウ
ム塩を溶出し、アセトンを留去した後、凍結乾
燥に付すとM−4′カルボン酸ナトリウム塩141
mgが得られた。
M−4′カルボン酸ナトリウム塩の物性値
1 NMRスペクトル
重メタノール中、内部標準にTMSを使用
して、60MHzで測定した。(CD3OD,δ:
ppm)
5.50(1H,ブロードの一重線)
5.70(1H,ブロードの一重線)
5.95(1H,四重線)
6.00(1H,二重線)
2 紫外部吸収スペクトル(メタノール溶液)
λnax(nm):230,238,246
3 赤外部吸収スペクトル(KBr法)cm-1:
3400,2900,1580
4 元素分析値(%) C23H35O7Naとして
理論値 C,61.88;H,7.85
実験値 C,61.85;H,7.95
(4) (1)の抽出液を飽和食塩水で洗浄し、次いでジ
アゾメタンのエーテル溶液を加えて30分間放置
後、減圧乾固した。次いで、得られた残留物を
ローバー・カラム(メルク社製,Si60サイズ
A)を用い、ベンゼン:アセトン=1:1の系
で精製すると、M−4′カルボン酸メチルエステ
ルの精製品150mgが無色油状物として得られた。
M−4′カルボン酸メチルエステルの物性値
1 NMRスペクトル
重クロロホルム中、内部標準にTMSを使
用して、60MHzで測定した。(CDCl3,δ:
ppm)
3.70(3H,一重線)
5.50(1H,ブロードの一重線)
5.75(1H,ブロードの一重線)
5.90(1H,四重線)
6.01(1H,二重線)
2 紫外部吸収スペクトル(メタノール溶液)
λnax(nm)230,238,246
3 赤外部吸収スペクトル(薄膜法)cm-1:
3400,1730
4 マススペクトル
N,O−ビス(トリメチルシリル)トリフ
ルオロアセトアミドでシリル化した後、日本
電子製D−300型を用いて測定した。
m/e:654(M+)
5 元素分析値(%) C24H38O7として
理論値 C,65.73;H,8.73
実験値 C,65.66;H,8.79
製造例2 M−4類
(1) 下記組成の培地100mlを含有する500ml容坂口
フラスコ20本にアブシデイア・コエルレアIFO
4423を植菌し、26℃,120s.p.m(strokes per
minute)で振盪培養し、2日後、ML−236B
カルボン酸ナトリウム塩を最終濃度で0.05%に
なるように添加して更に5日間26℃,120s.p.m
で培養した。
培地組成
グルコース 2.0%
K2HPO4 0.5
MgSO4・7H2O 0.15
NH4NO3 0.1
ペプトン 0.1
C.S.L 0.2
イーストエキストラクト 0.1
ZnSO4・7H2O 0.001
水道水 残
(PH7.0に調整)
培養終了後、変換反応液を過し、液をト
リフルオロ酢酸でPH3に調整した。次いで、1
の酢酸エチルで3回抽出するとM−4カルボ
ン酸を含む区分が得られた。
M−4カルボン酸の物性値
1 TLC
TLCプレート:メルク社製シリカゲルArt5715
溶媒;ベンゼン:アセトン:酢酸=50:50:3
Rf値 0.45
(2) (1)の抽出液を飽和食塩水で洗浄し、硫酸ナト
リウムで脱水後、触媒量のトリフルオロ酢酸を
添加してラクトン化した。次に5%炭酸水素ナ
トリウム水溶液で洗浄後、硫酸ナトリウムで脱
水し、濃縮乾固してラクトン体区分を得た。こ
れをローバー・カラム(メルク社,Si60サイズ
A)にかけ、酢酸エチルで溶出してM−4ラク
トン体区分を分離採取した。更にこれをローバ
ー・カラム(メルク社製,RP−8サイズA)
を用い、35%アセトニトリルで溶出し、精製し
た。
M−4ラクトン体の物性値
1 NMRスペクトル
重クロロホルム中、内部標準TMSを使用
して、100MHzで測定した。(CDCl3,δ:
ppm)
4.38(1H,多重線)
4.41(1H, 〃 )
4.62(1H, 〃 )
5.41(1H, 〃 )
5.58(1H,多重線)
5.90(1H,四重線)
6.01(1H,二重線)
2 紫外部吸収スペクトル(メタノール溶液)
λnax(nm):230,236.7,244.6
3 赤外部吸収スペクトル(薄膜法)cm-1:
3400,2950,1725
(3) (1)の抽出液を飽和食塩溶液で洗浄し、ジアゾ
メタンのエーテル溶液を加え、30分間放置後、
減圧乾固した。残渣をローバー・カラム(メル
ク社製,Si60サイズA)にかけ、ベンゼン:酢
酸エチル=1:1の系で溶出し、M−4メチル
エステルを含む区分を採取した。これをローバ
ー・カラム(メルク社製,RP−8サイズA)
を用い、35%アセトニトリルで溶出し、精製す
るとM−4カルボン酸メチルエステルの精製標
品20mgが無色油状物として得られた。
M−4カルボン酸メチルエステルの物性値
1 NMRスペクトル
重クロロホルム中、内部標準にTMSを使
用して200MHzで測定した。(CDCl3,δ:
ppm)
0.88(3H,t,J=7.3Hz)
0.89(3H,d,J=6.5Hz)
1.12(3H,d,J=6.8Hz)
1.1〜1.7(10H,m)
2.34(1H,sex,J=7Hz)
2.3〜2.5(2H,m)
2.49(2H,d,J=6.4Hz)
2.58(1H,m)
3.72(3H,s)
3.78(1H,m)
4.25(1H,quin,J=7Hz)
4.4(1H,m)
5.42(1H,m)
5.56(1H,m)
5.90(1H,d,d,J=9.8,5.6Hz)
5.99(1H,d,J=9.8Hz)
2 マススペクトル
N,O−ビス(トリメチルシリル)トリフルオ
ロアセトアミドでシリカ化した後、日本電子製D
−300型を用いて測定した。
m/e:654(M+),552,462,372,290,272,
233,231
3 紫外部吸収スペクトル(エタノール溶液)
λnax(nm):230.1,237.3,246.4
4 赤外部吸収スペクトル(薄膜法)cm-1:
3400,2950,1730
5 TLC
TLCプレート;メルク社製シリカゲルArt5715
溶媒;ペンゼン:アセトン=1:1
Rf値 0.88
(4) (2)で得られたM−4ラクトン体100mgを少量
のアセトンに溶解し、当量の水酸化ナトリウム
水溶液を添加して室温に1時間放置した。次い
でアセトンを留去後、凍結乾燥に付すとM−4
カルボン酸ナトリウム塩約105mgが得られた。
M−4カルボン酸ナトリウム塩の物性値
1 NMRスペクトル
メタノール中、内部標準にTMSを使用し
て200MHzで測定した(CD3OD,δ:ppm)
0.91(3H,t,J=7.5Hz)
0.92(3H,d,J=7Hz)
1.12(3H,d,J=7Hz)
1.1〜1.8(10H,m)
2.25(1H,d,d,J=15,7.6Hz)
2,34(1H,d,d,J=15,5.5Hz)
2.2〜2.4(3H,m)
2.48(1H,m)
3.68(1H,m)
4.07(1H,m)
4.28(1H,m)
5.36(1H,m)
5.48(1H,d,d,J=3,2Hz)
5.88(1H,d,d,J=9.6,5.3Hz)
5.98(1H,d,J=9.8Hz)
2 紫外部吸収スペクトル(メタノール溶液)
λnax:230.0,237.2,245.0
3 赤外部吸収スペクトル(KBr法)cm-1:
3400,2900,1725,1580
4 TLC
TLCプレート;メルク社製シリカゲルArt5715
溶媒;ベンゼン:アセトン:酢酸=50:50:
3
Rf値 0.45
製造例3 イソM−4′類
(1) 製造例2の(1)の培養により、抽出液にはM−
4カルボン酸と共にイソM−4′カルボン酸を含
む区分が得られ、イソM−4′カルボン酸のRf値
はM−4カルボン酸と同じであつた。
(2) 製造例2の(2)の処理において、トリフルオロ
酢酸でラクトン化後、ローバー・カラム(メル
ク社製,Si60サイズA)にかけ、酢酸エチルで
溶出する際にイソM−4′ラクトン体区分を分離
採取した。これを同様に精製して、イソM−
4′ラクトン体精製標品82mgが得られた。
イソM−4′ラクトン体の物性値
1 NMRスペクトル
重クロロホルム中、内部標準にTMSを使
用して100MHzで測定したNMRスペクトル
を第1図に示す。
2 紫外部吸収スペクトル(メタノール溶液)
λnaxnm:229,234.8,244.5
3 赤外部吸収スペクトル(薄膜法)cm-1:
第2図に示す。
4 TLC
TLCプレート:メルク社製シリカゲルArt
5715
溶媒;ベンゼン:アセトン:酢酸=50:50:
3
Rf値 0.62
(3) 製造例2の(3)の処理において、ジアゾメタン
でアルキル化後、ローバー・カラム(メルク社
製,Si60サイズA)にかけ、ベンゼン:酢酸エ
チルの系で溶出する際に、イソM−4′カルボン
酸メチルエステルを分離採取した。これを同様
に精製して、イソM−4′カルボン酸メチルエス
テルの精製標品78mgが得られた。
イソM−4′カルボン酸メチルエステルの物性値
1 NMRスペクトル
重クロロホルム中、内部標準にTMSを使
用して、100MHzで測定したNMRスペクト
ルを第3図に示す。
2 マススペクトル
N,O−ビス(トリメチルシリル)トリフルオ
ロアセトアミドでシリル化した後、日本電子製D
−300型を用いて測定した。
m/e:654(M+),552,462,372,272,233,
231
3 紫外部吸収スペクトル(メタノール溶液)
λnax(nm):229,234.8,244.5
4 赤外部吸収スペクトル(薄膜法)cm-1:第
4図に示す。
5 TLC
TLCプレート;メルク社製シリカゲルArt5715
溶媒;ベンゼン:アセトン=1:1
Rf値 0.88
(4) (2)で得られたイソM−4′ラクトン体100mgを
少量のアセトンに溶解し、当量の水酸化ナトリ
ウム水溶液を添加して室温に1時間放置した。
次いでアセトンを留去後、凍結乾燥に付すとイ
ソM−4′カルボン酸ナトリウム塩約103mgが得
られた。
イソM−4′カルボン酸ナトリウム塩の物性値
1 紫外部吸収スペクトル(メタノール溶液)
λnax(nm):229(sh),235,245(sh)
2 赤外部吸収スペクトル(KBr法)cm-1:
3400,2850,1710,1580
3 TLC
TLCプレート;メルク社製シリカゲルArt5715
溶媒;ベンゼン:アセトン:酢酸=50:50:
3
Rf値 0.45
製造例4 イソM−4類
(1) M−4カルボン酸ナトリウム塩50mgを水0ml
に溶解し、次いで1N塩酸でPH1.5に調整した。
この溶液を37℃で2時間撹拌した後、酢酸エチ
ル30mlで3回(30ml×3)抽出した。得られた
抽出液を約20mlまで濃縮し、次いで濃縮液を水
洗し脱水後、濃縮乾固するとイソM−4カルボ
ン酸を含む残留物が得られた。得られた残留物
をベンゼン10mlに溶解し、触媒量のp−トルエ
ンスルホン酸を加え50℃で15分間撹拌した。反
応終了後、反応混合物を水洗し濃縮乾固した。
得られた残留物をアセトニトリル1mlに溶解し
た。この溶液の100μlを高速液体クロマトグラ
フイー(カラム:Waters社製、Radial−pak
C−85mmi.d.、溶媒:25%アセトニトリル、流
速:2ml/min)に付し、14〜16分で溶出する
部分を分取した。この操作を10回くり返し、各
フラクシヨンをあわせた。溶出液よりアセトニ
トリルを留去し、残りの水層を1N塩酸でPH4
に調製した後、酢酸エチル10mlで3回(10ml×
3)抽出した。抽出液を水洗後、濃縮乾固する
と目的のイソM−4ラクトン体約1mgが得られ
た。
イソM−4ラクトン体の物性値
1 NMRスペクトル
重クロロホルム中、内部標準にTMSを使
用して200MHz(日本電子製JNM・FX−200
型)で測定した。(CDCl3,δ:ppm)
0.82(3H,d,J=7.1Hz)
0.86(3H,t,J=7.3〜7.6Hz)
1.08(3H,d,J=6.8Hz)
2.00(1H,dddd,J=14.4,3,1.5Hz)
2,10(1H,m)
2.15(1H,m)
2.33(1H,sex,J=7Hz)
2.42(2H,m)
2.64(1H,ddd,J=17.3,4,1.5Hz)
2.72(1H,dd,J=17.5,5Hz)
4.42(1H,br.)
4.39(1H,qu,J=4〜5Hz)
4.65(1H,m)
5.43(1H,br.)
5.61(1H,1対のm,J=9Hz)
5.49(1H,br.)
6.11(1H,d,br.J=9Hz)
2 紫外部吸収スペクトル
25%アセトニトリル溶液で測定((株)日立製作所
製124型)。
λnax(nm):232,238,245
3 マススペクトル
N,O−ビス(トリメチルシリル)トリフルオ
ロアセトアミドでシリル化した後、日本電子製D
−300型を用いて測定した。
m/e:550(M+),448,358,343,272,246,
233,231
製造例5 6−メトキシ−イソML−236類
(1) 下記組成の培地100mlを含有する500ml容三角
フラスコ20本にアブシジア・コエルレア
IFO4423を植菌し、26℃、220r.p.m.で振盪培養
し、4日後、ML−236Bラクトン体を最終濃度
で0.05%になるように添加して更に6日間26
℃、220r.p.m.で培養した。
培地組成
グルコース 2.0%
K2HPO4 0.15
MgSO4・7H2O 0.15
NH4NO3 0.1
ペプトン 0.1
C.S.L 0.2
イーストエキストラクト 0.1
ZnSO4・7H2O 0.001
水道水 残
(PH7.0に調整)
培養終了後、変換反応液を過し、液をト
リフルオロ酢酸でPH3に調整した。次いで、1
の酢酸エチルで3回抽出すると6−メトキシ
−イソML−236Bカルボン酸を含む区分が得ら
れた。上記抽出液を飽和食塩水で洗浄し、無水
硫酸ナトリウムで脱水後、触媒量のトリフルオ
ロ酢酸を添加してラクトン化した。次いで、上
記抽出液を5%炭酸水素ナトリウム水溶液で洗
浄し、無水硫酸ナトリウムで脱水後、減圧乾固
した。残留物をローバー・カラム(メルク社
製,Si60サイズA)用い、ベンゼン−アセトン
(7:3)系で溶出し、6−メトキシ−イソ
ML−236Bラクトン体を採取した。これを精製
すると目的物23mgが得られた。
6−メトキシ−イソML−236Bラクトン体の物性
値
1 NMRスペクトル(CDCl3,δ:ppm)
重クロロホルム中、内部標準にTMSを使
用して90MHzで測定した。
6.15(1H,二重線)
5.70(1H,四重線)
5.70(1H,多重線)
5.40(1H,多重線)
4.60(1H,多重線)
4.40(1H,多重線)
3.45(1H,二重線)
3.30(3H,一重線)
2 紫外部吸収スペクトル(メタノール溶液)
λnax(nm):235
3 赤外部吸収スペクトル(薄膜法)cm-1:
3450,1730
4 マススペクトル
m/e420(M+),402,318,300,286,268
5 TLC
TLCプレート;メルク社製シリカゲルArt5715
溶媒;ベンゼン:アセトン=1:1
Rf値 0.7
6 元素分析値(%) C24H36O6として
理論値 C,68.54;H,8.63
実験値 C,68.53;H,8.81
(2) 6−メトキシ−イソML−236Bラクトン体1g
を少量のアセトンに溶解し、次いで0.2N水酸
化ナトリウム水溶液13mlを添加して40℃で1時
間加水分解した。反応終了後、反応混合物より
アセトンを留去し、次いでクロロホルム5mlで
洗浄した。水層を0.1N塩酸でPH8.0に調整し、
ダイヤイオンHP−20カラム(三菱化成工業(株)
製品)に吸着させた。50%アセトンで6−メト
キシ−イソML236Bカルボン酸ナトリウム塩を
含有する区分を溶出し、アセトン留去した後、
凍結乾燥に付すと6−メトキシ−イソML−
236Bカルボン酸ナトリウム塩1.003gが得られ
た。
6−メトキシ−イソML−236Bカルボン酸ナトリ
ウム塩の物性値
1 NMRスペクトル
重メタノール中、内部標準にTMSを使用
して、60MHzで測定した。(CD3OD,δ:
ppm)
3.31(3H,一重線)
5.42(1H,多重線)
5.70(1H,多重線)
5.71(1H,四重線)
6.12(1H,二重線)
2 紫外部吸収スペクトル(メタノール溶液)
λnax(nm):235
3 赤外部吸収スペクトル(薄膜法)cm-1:
3400,2950,1580
4 元素分析値(%) C24H37O7Naとして
理論値 C,62.61;H,8.04
実験値 C,62.54;H,8.11
(3) 6−メトキシ−イソML−236Bカルボン酸ナ
トリウム塩1gを少量のメタノールに溶解し、
次いで冷却下でトリフルオロ酢酸を加えて酸性
とした後、直ちにジアゾメタン溶液を加えて30
分間放置した。反応終了後、反応混合物より溶
剤を留去した。得られた残留物をローバー・カ
ラム(メルク社製,RP−8サイズB)を用い、
メタノール:水=6:4の系で精製すると6−
メトキシ−イソML−236Bカルボン酸メチルエ
ステル780mgが無色油状物として得られた。
6−メトキシ−イソML−236Bカルボン酸メチル
エステルの物性値
1 NMRスペクトル
重クロロホルム中、内部標準にTMSを使
用して、60MHzで測定した。(CDCl3,δ:
ppm)
3.30(3H,一重線)
3.60(3H,一重線)
4.37(1H,多重線)
4.62(1H,多重線)
5.30(1H,多重線)
5.70(1H,多重線)
5.71(1H,四重線)
6.13(1H,二重線)
2 紫外部吸収スペクトル(メタノール溶液)
λnax(nm):235
3 赤外部吸収スペクトル(薄膜法)cm-1:
3400,1725
4 マススペクトル
N,O−ビス(トリメチルシリル)トリフルオ
ロアセトアミドでシリル化した後、日本電子製D
−300型を用いて測定した。
m/e:668(M+)
5 元素分析値(%) C25H40O7として
理論値 C,66.34;H,8.91
実験値 C,66.38;H,8.98
製造例6 3−ヒドロキシ−MB−530B類
(1) 下記組成の培地100mlを含有する500ml容三角
フラスコ20本にムコール・ヒイマリス・ホル
マ・ヒイマリスIFO5834を植菌し、26℃、
220r.p.m.で振盪培養し、4日後、MB−530B
ラクトン体を最終濃度で0.05%になるように添
加して更に6日間、26℃、220r.p.m.で培養し
た。
培地組成
グルコース 1.0%
ペプトン 0.2
肉エキス 0.1
酵母エキス 0.1
コーン・スチープリカー 0.3
水道水 残
(PH未修正)
培養終了後、変換反応液を過し、液をダ
イヤイオンHP−20(三菱化成工業(株)製品)を
用いたカラムに吸着させた。次いで70%メタノ
ールで溶出し、溶出液を留去した。次いでトリ
フルオロ酢酸でPH3.0に調整した。次いで酢酸
エチル1を用いて2回抽出すると3−ヒドロ
キシ−MB−530Bカルボン酸を含む区分が得
られた。
3−ヒドロキシ−MB−530Bカルボン酸の物性
値
1 TLC
TLCプレート:メルク製シリカゲルArt5715
溶媒;ベンゼン:アセトン:酢酸=50:50:
3
Rf値 0.47
(2) (1)で得られた抽出液にジアゾメタンのエーテ
ル溶液を加え、30分間放置した。次いで抽出液
を飽和食塩水で洗浄後、減圧乾固した。得られ
た残留物をマイクロボンダパツクC18(ウオータ
ーズ社製)に付し、53%メタノールで溶出し、
3−ヒドロキシ−MB−530Bカルボン酸メチ
ルエステルを含む区分を分離採取した。これを
精製し目的化合物180mgが得られた。
3−ヒドロキシ−MB−530Bカルボン酸メチル
エステルの物性値
1 NMRスペクトル
重クロロホルム中、内部標準にTMSを使
用して、90MHzで測定した。(CDCl3,δ:
ppm)
3.72(3H,一重線)
4.28(1H,五重線)
5.45(2H,多重線)
5.93(1H,四重線)
6.01(1H,二重線)
2 紫外部吸収スペクトル(メタノール溶液)
λnax(nm):229,236,244.5
3 赤外部吸収スペクトル(薄膜法)cm-1:
3410,2975,1730
4 元素分析値(%) C25H40O7として
理論値 C,66.34;H,8.91
実験値 C,66.30;H,9.02
(3) 3−ヒドロキシ−MB−530Bカルボン酸メ
チルエステル100mgを0.1N水酸化ナトリウム水
溶液に溶解し、30℃で1時間撹拌した。次いで
この溶液をクロロホルムを用いて洗浄し、凍結
乾燥に付すと、3−ヒドロキシ−MB−530B
カルボン酸ナトリウム塩393mgが得られた。
3−ヒドロキシ−MB−530Bカルボン酸ナト
リウム塩の物性値
1 NMRスペクトル
重水中、内部標準にDSSを使用して、90M
Hzで測定した。(D2O,δ:ppm)
5.40(2H,多重線)
5.89(1H,四重線)
6.00(1H,二重線)
2 紫外部吸収スペクトル(水溶液)
λnax:229,236,245
3 赤外部吸収スペクトル(KBr法)cm-1:
3400〜2900,1580
4 元素分析値(%) C24H37O7Naとして
理論値 C,62.59;H,8.097
実験値 C,62,37;H,8.21
製造例7 6−ヒドロキシ−イソMB−530B類
(1) 製造例5の(1)の培養により、抽出液には3−
ヒドロキシ−MB−530Bカルボン酸と共に6
−ヒドロキシ−イソMB−530Bカルボン酸を
含む区分が得られ、6−ヒドロキシ−イソMB
−530Bカルボン酸のRf値は3−ヒドロキシ−
MB−530Bカルボン酸と同じであつた。
(2) 製造例5の(1)の培養後、抽出液を飽和食塩水
で洗浄し、硫酸ナトリウムで乾燥後、トリフル
オロ酢酸の触媒量を加えた。次いで抽出液を5
%炭酸水素ナトリウム水溶液で洗浄し、硫酸ト
リウムで乾燥後、減圧乾固した。得られた残留
物をローバー・カラム(メルク社製,Si60サイ
ズA)を用い、酢酸エチルで溶出し、6−ヒド
ロキシ−イソMB−530Bラクトン体を分離採
取した。これを精製し、目的化合物212mgが得
られた。
6−ヒドロキシ−イソMB−530Bラクトン体
の物性値
1 NMRスペクトル
重アセトン中、内部標準にTMSを使用し
て、90MHzで測定した。(CD3COCD3,δ:
ppm)
3.94(1H,二重線)
4.35(1H,多重線)
4.68(1H,多重線)
5.45(1H,多重線)
5.62(1H,二重線)
5.91(1H,一重線)
2 紫外部吸収スペクトル(メタノール溶液)
λnax(nm):238.4
3 赤外部吸収スペクトル(KBr法)cm-1:
3450,1750
4 マススペクトル
m/e:420(M+)
5 元素分析値(%) C24H36O6として
理論値 C,68.54;H,8.63
実験値 C,68.33;H,8.81
(3) 6−ヒドロキシ−イソMB−530Bラクトン
体100mgを少量のアセトンに溶解し、次いで当
量の0.2N水酸化ナトリウム水溶液を加えて、
室温で撹拌した。次いでこの溶液を凍結乾燥に
付し、6−ヒドロキシ−イソMB−530Bカル
ボン酸ナトリウム塩106mgが得られた。
6−ヒドロキシ−イソMB−530Bカルボン酸
ナトリウム塩の物性値
1 NMRスペクトル
重水中、内部標準にDSSを使用して、90M
Hzで測定した。(D2O,δ:ppm)
3.78(1H,多重線)
4.01(1H,多重線)
4.13(1H,多重線)
5.49(1H,多重線)
5.62(1H,多重線)
6.02(1H,巾広い一重線)
2 柴外部吸収スペクトル(水溶液)
λnx(nm):238
3 赤外部吸収スペトル(KBr法)cm-1:3400
〜2900,1575
4 元素分析値(%) C24H37O7Naとして
理論値 C,62.59;H,8.097
実験値 C,62.28;H,8.31
(4) 製造例5の(2)の処理において、ジアゾメタン
でアルキル化後、マイクロボンダパツクC18に
付し、53%メタノールで溶出し、6−ヒドロキ
シ−イソMB−530Bカルボン酸メチルエステ
ルを含む区分を分離採取した。こを精製し目的
化合物170mgが得られた。
6−ヒドロキシ−イソMB−530Bカルボン酸
メチルエステルの物性値
(1) NMRスペクトル
重アセトン中、内部標準にTMSを使用し
て、90MHzで測定した。(CD3COCD3,δ:
ppm)
3.70(3H,一重線)
4.22(1H,多重線)
5.42(1H,多重線)
5.57(1H,多重線)
5.92(1H,二重線)
2 紫外部吸収スペクトル(メタノール溶液)
λnax(nm):238.4
3 赤外部吸収スペクトル(薄膜法)cm-1:
3400,2960,1732
4 元素分析値(%) C25H40O7として
理論値 C,66.34;H,8.91
実験値 C,66.28;H,8.99
本発明の前記式()または()を有するカ
ルボン酸、その薬理上許容しうる塩、その低級ア
ルキルエステルまたはそのラクトン体は高血清過
酸化脂質血症治療剤の有効成分である。その投与
形態としては例えば錠剤、カプセル剤、顆粒剤、
散剤、シロツプ剤などによる経口投与法あるいは
皮不注射、静脈内注射、坐剤などによる非経口投
与法があげられる。これらの各種製剤は常法に従
つて、目的に応じて主薬に溶解補助剤、懸濁化
剤、賦形剤、結合剤、崩壊剤、滑沢剤、矯味剤な
ど製剤技術分野において通常使用し得る既知の補
助剤を用いて製剤化することができる。その使用
量は症状、年令、体重等および使用経路、使用回
数によつて異なるが、通常成人に対してM−4類
化合物では0.05〜25mg/Kg/日、好適には0.2〜
20mg/Kg/日であり、M−4′類化合物、イソM−
4類化合物およびイソM−4′類化合物では0.1〜
50mg/Kg/日、好適には0.5〜25mg/Kg/日であ
り、3−ヒドロキシ−MB−530B類化合物およ
び6−ヒドロキシ−イソMB−530B類化合物で
は0.05〜25mg/Kg/日、好適には0.2〜20mg/
Kg/日であり、−6メトキシ−イソML−236B類
化合物では0.05〜50mg/Kg/日、好適には0.5〜
30mg/Kg/日である。より大量の投与は必要に応
じて行うことができる。
急性毒性
例えばM−4カルボン酸ナトリウム塩の急性毒
性はマウスに対して、LD50(mg/Kg)が経口投与
で8000mg/Kg以上であり、静脈内注射で2000mg/
Kg以上であつた。また、ラツトに対してLD50
(mg/Kg)が経口投与で12000mg/Kg以上であり、
静脈内注射で400mg/Kg以上であつた。
次に実施例を示す。
実施例 1
ビーグル犬の2群(1群は雄性3匹、他の一群
は雌性3匹からなる)を用意した。これらの群に
M−4カルボン酸酸ナトリウム塩25mg/Kg/日を
1日1回で5週間連続して経口投与した。投与前
および投与後のこれらのビーグル犬の血中過酸化
脂質値を微量螢光法〔バイオケミカル・メデイシ
ン(Biochem.Med.)15巻,212〜216頁,1976
年〕によつて測定した。結果を表1に示す。
The present invention is based on the formula or (In the formula, R 1 represents a hydrogen atom or a methyl group,
R 2 represents a hydrogen atom or a methyl group, and R 5 represents a hydroxyl group or a methoxy group. ), a pharmacologically acceptable salt thereof, a lower alkyl ester thereof, or a lactone thereof as an active ingredient. It has been previously known that ML-236B is useful as a therapeutic agent for hyperlipidemia peroxidation (Japanese Patent Application Laid-Open No. 1986-
(See Publication No. 110618). The present inventors have now determined that the formula () or ()
It has been found that a compound having the following properties and its derivatives are effective in treating hyperlipidemia peroxidation. The derivative of the carboxylic acid having the formula () or () used in the present invention is a pharmacologically acceptable salt thereof, a lower alkyl ester thereof, or a lactone thereof. A pharmacologically acceptable salt of a carboxylic acid having the above formula () or (), such as an alkali metal salt such as thorium or potassium. Lower alkyl esters of carboxylic acids having the formula () or () are, for example, compounds such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl and the like. The lactone form of the compound having the formula () or () is a compound in which the substituent at the 8-position of hexahydronaphthalic acid has the following partial structural formula. In the above formula (), the compound in which R 1 is a hydrogen atom is 3-hydroxy-ML-236B,
Compounds whose 3-position substituent is 〓OH are M-4 class,
...OH compounds are abbreviated as M-4's. This compound is disclosed in Japanese Patent Application Laid-Open No. 57-50894 and Japanese Patent Application No. 56-105967.
The manufacturing method is described in the patent specification. In the above formula (), compounds in which R 1 is a methyl group are hereinafter abbreviated as 3-hydroxy-MB-530Bs. This compound is described in Japanese Patent Application No. Sho 56-134558, together with its manufacturing method. In the formula (), R 2 is a hydrogen atom,
Compounds in which R 3 is a hydroxyl group are 6-hydroxy-isoML-236B, and the substituent at the 6th position is
OH compounds are abbreviated as isoM-4s, ...OH compounds are abbreviated as isoM-4's. This compound was patented in 1982.
-195160, JP-A-57-108039 and JP-A-57
It is described in the specification of No.-50894 along with its manufacturing method. In the formula (), R 2 is a hydrogen atom,
Compounds in which R 3 is a methoxy group are hereinafter abbreviated as 6-methoxy-iso ML-236Bs. This compound is described in Japanese Patent Application No. Sho 56-114038, together with its manufacturing method. In the formula (), R 2 is a methyl group,
Compounds in which R 3 is a hydroxyl group are hereinafter abbreviated as 6-hydroxy-isoMB-530Bs. This compound is described in Japanese Patent Application No. Sho 56-134558, together with its manufacturing method. The compound having the above formula () or () is
It can be obtained by enzymatic hydroxylation using microorganisms using the MB-530B or ML-236B or derivatives thereof as a raw material compound according to the method described in the patent application specification. Examples of producing these compounds will be described below. Production Example 1 M-4′ (1) Twenty 500 ml Erlenmeyer flasks containing 100 ml of a medium with the following composition were inoculated with Synthephalastrum nigricans SANK42372 (Feikoken Bacteria No. 6043), and incubated at 26°C. After 3 days of shaking culture at 220 rpm, the final concentration of ML-236B lactone was 0.05%.
26℃ for another 6 days.
Cultured at 220 rpm. Medium composition Glucose 1.0% Peptone 0.2 Meat extract 0.1 Yeast extract 0.1 Corn stew liquor 0.3 Tap water Remaining (PH not corrected) After completion of the culture, the conversion reaction solution was filtered and the pH of the solution was adjusted to 3 with trifluoroacetic acid. It was then extracted three times with ethyl acetate in 1 to obtain a fraction containing the M-4' carboxylic acid. Physical properties of M-4′ carboxylic acid 1 TLC TLC plate: Merck silica gel
Art5715 Solvent; Benzene: Acetone: Acetic acid = 50:50:
3 Rf value 0.46 (2) The extract of (1) was washed with saturated saline, dehydrated with sodium sulfate, and then lactonized by adding a catalytic amount of trifluoroacetic acid. Next, the above extract was washed with a 5% aqueous sodium bicarbonate solution, dehydrated with sodium sulfate, and then dried under reduced pressure. Next, the obtained residue was eluted with benzene:acetone = 7:3 using a Rover column (manufactured by Merck & Co., Si60 size A) to collect the M-4' lactone body, and further eluted with ethyl acetate. After recrystallization, about 180 mg of M-4' lactone was obtained. Physical properties of M-4' lactone 1 NMR spectrum Measured at 100MHz in deuterated chloroform using TMS as an internal standard. (CDCl 3 , δ: ppm) 4.25 (1H, multiplet) 4.60 (1H, multiplet) 5.50 (1H, multiplet) 5.75 (1H, multiplet) 5.90 (1H, quartet) 6.01 (1H, multiplet) 2 Ultraviolet absorption spectrum (methanol solution) λmax (nm): 230, 237, 245 3 Infrared absorption spectrum (KBr method) cm -1 : 3500, 1720 4 Mass spectrum m/e: 406 (M + ), 304, 286 5 Optical rotation [α] D: +310.9° (C = 0.66, methanol) 6 Melting point 141-143°C 7 Elemental analysis value (%) As C 23 H 34 O 6 Theoretical value C, 67.95; H, 8.43 Experimental value C, 68.05; H, 8.37 8 TLC TLC plate: Merck silica gel Art5715 Solvent: Benzene: Acetone = 1:1 Rf value 0.64 (3) The extract of (1) was washed with saturated saline, and then 5
A fraction containing M-4' carboxylic acid sodium salt was obtained by dissolving the mixture into the aqueous layer using a % sodium bicarbonate aqueous solution. This aqueous layer was adjusted to pH 8.0 with 0.1N hydrochloric acid, and then the fraction containing M-4' carboxylic acid sodium salt was mixed with Diaion HP-
20 column (manufactured by Mitsubishi Chemical Industries, Ltd.). M-4' carboxylic acid sodium salt was eluted with 50% acetone, the acetone was distilled off, and then freeze-dried to yield M-4' carboxylic acid sodium salt 141
mg was obtained. Physical properties of M-4' carboxylic acid sodium salt 1 NMR spectrum Measured at 60MHz in heavy methanol using TMS as an internal standard. (CD 3 OD, δ:
ppm) 5.50 (1H, broad singlet) 5.70 (1H, broad singlet) 5.95 (1H, quartet) 6.00 (1H, doublet) 2 Ultraviolet absorption spectrum (methanol solution) λ nax (nm) : 230, 238, 246 3 Infrared absorption spectrum (KBr method) cm -1 : 3400, 2900, 1580 4 Elemental analysis value (%) C 23 H 35 O 7 As Na Theoretical value C, 61.88; H, 7.85 Experimental value C, 61.85; H, 7.95 (4) The extract of (1) was washed with saturated brine, then an ether solution of diazomethane was added, and after standing for 30 minutes, it was dried under reduced pressure. Next, the obtained residue was purified using a Lorber column (manufactured by Merck & Co., Si60 size A) in a benzene:acetone = 1:1 system, and 150 mg of the purified product of M-4' carboxylic acid methyl ester was obtained as colorless. Obtained as an oil. Physical properties of M-4' carboxylic acid methyl ester 1 NMR spectrum Measured at 60MHz in deuterated chloroform using TMS as an internal standard. (CDCl 3 , δ:
ppm) 3.70 (3H, singlet) 5.50 (1H, broad singlet) 5.75 (1H, broad singlet) 5.90 (1H, quartet) 6.01 (1H, doublet) 2 Ultraviolet absorption spectrum (methanol Solution) λ nax (nm) 230, 238, 246 3 Infrared absorption spectrum (thin film method) cm -1 : 3400, 1730 4 Mass spectrum After silylation with N,O-bis(trimethylsilyl)trifluoroacetamide, JEOL The measurement was carried out using a model D-300 manufactured by Kogyo Corporation. m/e: 654 (M + ) 5 Elemental analysis value (%) As C 24 H 38 O 7 Theoretical value C, 65.73; H, 8.73 Experimental value C, 65.66; H, 8.79 Production example 2 M-4 class (1 ) Absidia coerulea IFO in 20 500 ml Sakaguchi flasks containing 100 ml of medium with the following composition.
4423, 26℃, 120s.pm (strokes per
After 2 days, ML-236B
Add sodium carboxylic acid salt to a final concentration of 0.05% and incubate for another 5 days at 26°C, 120s.pm.
It was cultured in Medium composition Glucose 2.0% K 2 HPO 4 0.5 MgSO 4・7H 2 O 0.15 NH 4 NO 3 0.1 Peptone 0.1 CSL 0.2 Yeast extract 0.1 ZnSO 4・7H 2 O 0.001 Tap water Remaining (adjusted to PH7.0) After completion of culture The conversion reaction solution was filtered, and the pH of the solution was adjusted to 3 with trifluoroacetic acid. Then 1
After extraction with ethyl acetate three times, a fraction containing M-4 carboxylic acid was obtained. Physical properties of M-4 carboxylic acid 1 TLC TLC plate: Merck Silica Gel Art5715 Solvent: Benzene: Acetone: Acetic acid = 50:50:3 Rf value 0.45 (2) The extract from (1) was washed with saturated saline. After dehydration with sodium sulfate, a catalytic amount of trifluoroacetic acid was added for lactonization. Next, after washing with a 5% aqueous sodium bicarbonate solution, it was dehydrated with sodium sulfate and concentrated to dryness to obtain a lactone fraction. This was applied to a Rover column (Merck & Co., Si60 size A) and eluted with ethyl acetate to separate and collect the M-4 lactone fraction. Furthermore, this was connected to a Rover column (manufactured by Merck & Co., RP-8 size A).
The product was purified using 35% acetonitrile and eluted with 35% acetonitrile. Physical properties of M-4 lactone 1 NMR spectrum Measured at 100MHz in deuterated chloroform using internal standard TMS. (CDCl 3 , δ:
ppm) 4.38 (1H, multiplet) 4.41 (1H, 〃 ) 4.62 (1H, 〃 ) 5.41 (1H, 〃 ) 5.58 (1H, multiplet) 5.90 (1H, quartet) 6.01 (1H, doublet) 2 Ultraviolet absorption spectrum (methanol solution) λ nax (nm): 230, 236.7, 244.6 3 Infrared absorption spectrum (thin film method) cm -1 : 3400, 2950, 1725 (3) Add the extract of (1) to saturated salt. Wash with solution, add ethereal solution of diazomethane, leave for 30 minutes, then
It was dried under reduced pressure. The residue was applied to a Rover column (manufactured by Merck & Co., Si60 size A), eluted with a benzene:ethyl acetate = 1:1 system, and a fraction containing M-4 methyl ester was collected. Rover column (Merck, RP-8 size A)
After purification using 35% acetonitrile as elution, 20 mg of a purified sample of M-4 carboxylic acid methyl ester was obtained as a colorless oil. Physical properties of M-4 carboxylic acid methyl ester 1 NMR spectrum Measured at 200MHz in deuterated chloroform using TMS as an internal standard. (CDCl 3 , δ:
ppm) 0.88 (3H, t, J = 7.3Hz) 0.89 (3H, d, J = 6.5Hz) 1.12 (3H, d, J = 6.8Hz) 1.1~1.7 (10H, m) 2.34 (1H, sex, J =7Hz) 2.3~2.5 (2H, m) 2.49 (2H, d, J = 6.4Hz) 2.58 (1H, m) 3.72 (3H, s) 3.78 (1H, m) 4.25 (1H, quin, J = 7Hz) 4.4 (1H, m) 5.42 (1H, m) 5.56 (1H, m) 5.90 (1H, d, d, J = 9.8, 5.6Hz) 5.99 (1H, d, J = 9.8Hz) 2 Mass spectrum N, O - After silicification with bis(trimethylsilyl)trifluoroacetamide, JEOL D
Measured using Model -300. m/e: 654 (M + ), 552, 462, 372, 290, 272,
233, 231 3 Ultraviolet absorption spectrum (ethanol solution) λ nax (nm): 230.1, 237.3, 246.4 4 Infrared absorption spectrum (thin film method) cm -1 : 3400, 2950, 1730 5 TLC TLC plate; Merck silica gel Art5715 Solvent; Penzene: Acetone = 1:1 Rf value 0.88 (4) 100 mg of the M-4 lactone obtained in (2) was dissolved in a small amount of acetone, an equivalent amount of sodium hydroxide aqueous solution was added, and the solution was heated to room temperature. I left it for a while. Then, after distilling off the acetone, it was freeze-dried to obtain M-4.
Approximately 105 mg of carboxylic acid sodium salt was obtained. Physical properties of M-4 carboxylic acid sodium salt 1 NMR spectrum Measured in methanol at 200MHz using TMS as an internal standard (CD 3 OD, δ: ppm) 0.91 (3H, t, J = 7.5Hz) 0.92 ( 3H, d, J = 7Hz) 1.12 (3H, d, J = 7Hz) 1.1~1.8 (10H, m) 2.25 (1H, d, d, J = 15, 7.6Hz) 2, 34 (1H, d, d , J=15, 5.5Hz) 2.2~2.4 (3H, m) 2.48 (1H, m) 3.68 (1H, m) 4.07 (1H, m) 4.28 (1H, m) 5.36 (1H, m) 5.48 (1H, d, d, J = 3, 2 Hz) 5.88 (1H, d, d, J = 9.6, 5.3 Hz) 5.98 (1H, d, J = 9.8 Hz) 2 Ultraviolet absorption spectrum (methanol solution) λ nax : 230.0, 237.2, 245.0 3 Infrared absorption spectrum (KBr method) cm -1 : 3400, 2900, 1725, 1580 4 TLC TLC plate; Merck silica gel Art5715 Solvent; Benzene: Acetone: Acetic acid = 50:50:
3 Rf value 0.45 Production Example 3 IsoM-4′ (1) By culturing in Production Example 2 (1), the extract contains M-
A section containing isoM-4'carboxylic acid as well as 4carboxylic acid was obtained, and the Rf value of isoM-4'carboxylic acid was the same as that of M-4carboxylic acid. (2) In the treatment of (2) of Production Example 2, after lactonization with trifluoroacetic acid, it was applied to a Lorber column (manufactured by Merck & Co., Si60 size A), and when eluted with ethyl acetate, the isoM-4' lactone was The sections were separated and sampled. This was purified in the same way and isoM-
82 mg of purified 4' lactone product was obtained. Physical properties of isoM-4' lactone 1 NMR spectrum Figure 1 shows the NMR spectrum measured at 100MHz in deuterated chloroform using TMS as an internal standard. 2 Ultraviolet absorption spectrum (methanol solution) λ nax nm: 229, 234.8, 244.5 3 Infrared absorption spectrum (thin film method) cm -1 : Shown in Figure 2. 4 TLC TLC plate: Merck Silica Gel Art
5715 Solvent; Benzene: Acetone: Acetic acid = 50:50:
3 Rf value 0.62 (3) In the treatment of (3) of Production Example 2, after alkylation with diazomethane, it was applied to a Rover column (manufactured by Merck & Co., Si60 size A) and eluted with a benzene:ethyl acetate system. IsoM-4'carboxylic acid methyl ester was separated and collected. This was purified in the same manner to obtain 78 mg of a purified sample of isoM-4'carboxylic acid methyl ester. Physical properties of isoM-4'carboxylic acid methyl ester 1 NMR spectrum The NMR spectrum measured at 100MHz in deuterated chloroform using TMS as an internal standard is shown in Figure 3. 2 Mass spectrum After silylation with N,O-bis(trimethylsilyl)trifluoroacetamide, JEOL D
Measured using Model -300. m/e: 654 (M + ), 552, 462, 372, 272, 233,
231 3 Ultraviolet absorption spectrum (methanol solution) λ nax (nm): 229, 234.8, 244.5 4 Infrared absorption spectrum (thin film method) cm -1 : Shown in Figure 4. 5 TLC TLC plate: Silica gel Art5715 manufactured by Merck & Co. Solvent: Benzene: Acetone = 1:1 Rf value 0.88 (4) 100 mg of the isoM-4' lactone obtained in (2) was dissolved in a small amount of acetone, and an equivalent amount of An aqueous sodium hydroxide solution was added and the mixture was left at room temperature for 1 hour.
After distilling off the acetone, the residue was freeze-dried to obtain about 103 mg of isoM-4'carboxylic acid sodium salt. Physical properties of isoM-4' carboxylic acid sodium salt 1 Ultraviolet absorption spectrum (methanol solution) λ nax (nm): 229 (sh), 235, 245 (sh) 2 Infrared absorption spectrum (KBr method) cm -1 : 3400, 2850, 1710, 1580 3 TLC TLC plate; Merck silica gel Art5715 Solvent; Benzene: Acetone: Acetic acid = 50:50:
3 Rf value 0.45 Production example 4 Iso M-4 class (1) 50 mg of M-4 carboxylic acid sodium salt is added to 0 ml of water.
and then adjusted to pH 1.5 with 1N hydrochloric acid.
This solution was stirred at 37° C. for 2 hours, and then extracted three times (30 ml×3) with 30 ml of ethyl acetate. The obtained extract was concentrated to about 20 ml, and then the concentrated solution was washed with water, dehydrated, and concentrated to dryness to obtain a residue containing isoM-4 carboxylic acid. The obtained residue was dissolved in 10 ml of benzene, a catalytic amount of p-toluenesulfonic acid was added, and the mixture was stirred at 50°C for 15 minutes. After the reaction was completed, the reaction mixture was washed with water and concentrated to dryness.
The resulting residue was dissolved in 1 ml of acetonitrile. 100 μl of this solution was subjected to high-performance liquid chromatography (column: Waters, Radial-pak).
C-85 mmi.d., solvent: 25% acetonitrile, flow rate: 2 ml/min), and the portion eluted in 14 to 16 minutes was fractionated. This operation was repeated 10 times and each fraction was combined. Acetonitrile was distilled off from the eluate, and the remaining aqueous layer was diluted to pH4 with 1N hydrochloric acid.
After preparing the solution, add 10 ml of ethyl acetate three times (10 ml x
3) Extracted. After washing the extract with water, it was concentrated to dryness to obtain about 1 mg of the desired isoM-4 lactone. Physical properties of isoM-4 lactone 1 NMR spectrum 200MHz (JNM/FX-200 manufactured by JEOL Ltd.) using TMS as an internal standard in deuterated chloroform
(type). (CDCl 3 , δ: ppm) 0.82 (3H, d, J = 7.1Hz) 0.86 (3H, t, J = 7.3 to 7.6Hz) 1.08 (3H, d, J = 6.8Hz) 2.00 (1H, dddd, J =14.4, 3, 1.5Hz) 2,10 (1H, m) 2.15 (1H, m) 2.33 (1H, sex, J = 7Hz) 2.42 (2H, m) 2.64 (1H, ddd, J = 17.3, 4, 1.5Hz) 2.72 (1H, dd, J = 17.5, 5Hz) 4.42 (1H, br.) 4.39 (1H, qu, J = 4~5Hz) 4.65 (1H, m) 5.43 (1H, br.) 5.61 (1H , a pair of m, J = 9Hz) 5.49 (1H, br.) 6.11 (1H, d, br.J = 9Hz) 2 Ultraviolet absorption spectrum Measured with 25% acetonitrile solution (Model 124, manufactured by Hitachi, Ltd.) . λ nax (nm): 232, 238, 245 3 Mass spectrum After silylation with N,O-bis(trimethylsilyl)trifluoroacetamide, JEOL D
Measured using Model -300. m/e: 550 (M + ), 448, 358, 343, 272, 246,
233, 231 Production Example 5 6-methoxy-iso ML-236 class (1) Absidia coerulea was placed in 20 500 ml Erlenmeyer flasks containing 100 ml of a medium with the following composition.
IFO4423 was inoculated and cultured with shaking at 26°C and 220 rpm. After 4 days, ML-236B lactone was added to a final concentration of 0.05%, and the mixture was further incubated for 6 days.
Cultured at 220 rpm. Medium composition Glucose 2.0% K 2 HPO 4 0.15 MgSO 4・7H 2 O 0.15 NH 4 NO 3 0.1 Peptone 0.1 CSL 0.2 Yeast extract 0.1 ZnSO 4・7H 2 O 0.001 Tap water Remaining (adjusted to PH7.0) After completion of culture The conversion reaction solution was filtered, and the pH of the solution was adjusted to 3 with trifluoroacetic acid. Then 1
Extraction three times with ethyl acetate yielded a fraction containing 6-methoxy-iso ML-236B carboxylic acid. The above extract was washed with saturated brine, dehydrated with anhydrous sodium sulfate, and then lactonized by adding a catalytic amount of trifluoroacetic acid. Next, the above extract was washed with a 5% aqueous sodium bicarbonate solution, dehydrated with anhydrous sodium sulfate, and then dried under reduced pressure. The residue was eluted with a benzene-acetone (7:3) system using a Rover column (manufactured by Merck & Co., Si60 size A), and 6-methoxy-iso
ML-236B lactone body was collected. When this was purified, 23 mg of the target product was obtained. Physical properties of 6-methoxy-iso ML-236B lactone 1 NMR spectrum (CDCl 3 , δ: ppm) Measured in deuterated chloroform at 90 MHz using TMS as an internal standard. 6.15 (1H, doublet) 5.70 (1H, quartet) 5.70 (1H, multiplet) 5.40 (1H, multiplet) 4.60 (1H, multiplet) 4.40 (1H, multiplet) 3.45 (1H, doublet) line) 3.30 (3H, singlet) 2 Ultraviolet absorption spectrum (methanol solution) λ nax (nm): 235 3 Infrared absorption spectrum (thin film method) cm -1 : 3450, 1730 4 Mass spectrum m/e420 (M + ), 402, 318, 300, 286, 268 5 TLC TLC plate; Merck Silica Gel Art5715 Solvent; Benzene: Acetone = 1:1 Rf value 0.7 6 Elemental analysis value (%) As C 24 H 36 O 6 Theoretical value C , 68.54; H, 8.63 Experimental value C, 68.53; H, 8.81 (2) 6-methoxy-iso ML-236B lactone 1 g
was dissolved in a small amount of acetone, and then 13 ml of 0.2N aqueous sodium hydroxide solution was added and hydrolyzed at 40°C for 1 hour. After the reaction was completed, acetone was distilled off from the reaction mixture, and then washed with 5 ml of chloroform. Adjust the aqueous layer to PH8.0 with 0.1N hydrochloric acid,
Diaion HP-20 column (Mitsubishi Chemical Industries, Ltd.)
product). Elute the fraction containing 6-methoxy-iso ML236B carboxylic acid sodium salt with 50% acetone, and after distilling off the acetone,
When freeze-dried, 6-methoxy-isoML-
1.003 g of 236B carboxylic acid sodium salt was obtained. Physical properties of 6-methoxy-iso ML-236B carboxylic acid sodium salt 1 NMR spectrum Measured at 60 MHz in deuterated methanol using TMS as an internal standard. (CD 3 OD, δ:
ppm) 3.31 (3H, singlet) 5.42 (1H, multiplet) 5.70 (1H, multiplet) 5.71 (1H, quartet) 6.12 (1H, doublet) 2 Ultraviolet absorption spectrum (methanol solution) λ nax (nm): 235 3 Infrared absorption spectrum (thin film method) cm -1 :
3400, 2950, 1580 4 Elemental analysis value (%) C 24 H 37 O 7 As Na Theoretical value C, 62.61; H, 8.04 Experimental value C, 62.54; H, 8.11 (3) 6-methoxy-iso ML-236B carvone Dissolve 1 g of acid sodium salt in a small amount of methanol,
Next, add trifluoroacetic acid under cooling to make it acidic, and then immediately add diazomethane solution for 30 minutes.
Leave it for a minute. After the reaction was completed, the solvent was distilled off from the reaction mixture. The obtained residue was purified using a Rover column (manufactured by Merck & Co., RP-8 size B).
When purified in a methanol:water = 6:4 system, 6-
780 mg of methoxy-iso ML-236B carboxylic acid methyl ester was obtained as a colorless oil. Physical properties of 6-methoxy-iso ML-236B carboxylic acid methyl ester 1 NMR spectrum Measured at 60 MHz in deuterated chloroform using TMS as an internal standard. (CDCl 3 , δ:
ppm) 3.30 (3H, singlet) 3.60 (3H, singlet) 4.37 (1H, multiplet) 4.62 (1H, multiplet) 5.30 (1H, multiplet) 5.70 (1H, multiplet) 5.71 (1H, multiplet) line) 6.13 (1H, double line) 2 Ultraviolet absorption spectrum (methanol solution) λ nax (nm): 235 3 Infrared absorption spectrum (thin film method) cm -1 : 3400, 1725 4 Mass spectrum N,O-bis After silylation with (trimethylsilyl)trifluoroacetamide, JEOL D
Measured using Model -300. m/e: 668 (M + ) 5 Elemental analysis value (%) As C 25 H 40 O 7 Theoretical value C, 66.34; H, 8.91 Experimental value C, 66.38; H, 8.98 Production example 6 3-hydroxy-MB- Class 530B (1) Inoculate 20 500 ml Erlenmeyer flasks containing 100 ml of the medium with the following composition with Mucor hyimaris IFO5834, and incubate at 26℃.
After 4 days of shaking culture at 220rpm, MB-530B
Lactone bodies were added to the final concentration of 0.05%, and the cells were further cultured at 26° C. and 220 rpm for 6 days. Medium composition Glucose 1.0% Peptone 0.2 Meat extract 0.1 Yeast extract 0.1 Corn steep liquor 0.3 Tap water Remaining (PH uncorrected) After the cultivation, filter the conversion reaction solution and transfer the solution to Diaion HP-20 (Mitsubishi Chemical Corporation) product) was adsorbed onto a column using the product. Next, elution was performed with 70% methanol, and the eluate was distilled off. Then, the pH was adjusted to 3.0 with trifluoroacetic acid. Two extractions with 1 portion of ethyl acetate then yielded a fraction containing 3-hydroxy-MB-530B carboxylic acid. Physical properties of 3-hydroxy-MB-530B carboxylic acid 1 TLC TLC plate: Merck silica gel Art5715 Solvent: Benzene: Acetone: Acetic acid = 50:50:
3 Rf value 0.47 (2) An ether solution of diazomethane was added to the extract obtained in (1) and left for 30 minutes. The extract was then washed with saturated brine and dried under reduced pressure. The obtained residue was applied to Microbondapak C 18 (manufactured by Waters) and eluted with 53% methanol.
The fraction containing 3-hydroxy-MB-530B carboxylic acid methyl ester was separated and collected. This was purified to obtain 180 mg of the target compound. Physical properties of 3-hydroxy-MB-530B carboxylic acid methyl ester 1 NMR spectrum Measured at 90MHz in deuterated chloroform using TMS as an internal standard. (CDCl 3 , δ:
ppm) 3.72 (3H, singlet) 4.28 (1H, quintet) 5.45 (2H, multiplet) 5.93 (1H, quartet) 6.01 (1H, doublet) 2 Ultraviolet absorption spectrum (methanol solution) λ nax (nm): 229, 236, 244.5 3 Infrared absorption spectrum (thin film method) cm -1 : 3410, 2975, 1730 4 Elemental analysis value (%) C 25 H 40 O 7 Theoretical value C, 66.34; H, 8.91 Experimental value C, 66.30; H, 9.02 (3) 100 mg of 3-hydroxy-MB-530B carboxylic acid methyl ester was dissolved in a 0.1N aqueous sodium hydroxide solution and stirred at 30°C for 1 hour. This solution was then washed with chloroform and lyophilized to yield 3-hydroxy-MB-530B.
393 mg of carboxylic acid sodium salt was obtained. Physical properties of 3-hydroxy-MB-530B carboxylic acid sodium salt 1 NMR spectrum 90M in heavy water using DSS as an internal standard
Measured in Hz. (D 2 O, δ: ppm) 5.40 (2H, multiplet) 5.89 (1H, quartet) 6.00 (1H, doublet) 2 Ultraviolet absorption spectrum (aqueous solution) λ nax :229, 236, 245 3 Red External absorption spectrum (KBr method) cm -1 : 3400-2900, 1580 4 Elemental analysis value (%) As C 24 H 37 O 7 Na Theoretical value C, 62.59; H, 8.097 Experimental value C, 62, 37; H, 8.21 Production Example 7 6-Hydroxy-isoMB-530B (1) By culturing in Production Example 5 (1), the extract contains 3-
Hydroxy-MB-530B with carboxylic acid 6
-Hydroxy-isoMB-530B A section containing carboxylic acid is obtained, 6-hydroxy-isoMB
The Rf value of -530B carboxylic acid is 3-hydroxy-
It was the same as MB-530B carboxylic acid. (2) After culturing in (1) of Production Example 5, the extract was washed with saturated saline, dried over sodium sulfate, and then a catalytic amount of trifluoroacetic acid was added. Next, add the extract to 5
% aqueous sodium bicarbonate solution, dried over thorium sulfate, and then dried under reduced pressure. The resulting residue was eluted with ethyl acetate using a Rover column (manufactured by Merck & Co., Si60 size A) to separate and collect the 6-hydroxy-isoMB-530B lactone. This was purified to obtain 212 mg of the target compound. Physical properties of 6-hydroxy-isoMB-530B lactone 1 NMR spectrum Measured at 90MHz in deuterated acetone using TMS as an internal standard. (CD 3 COCD 3 , δ:
ppm) 3.94 (1H, doublet) 4.35 (1H, multiplet) 4.68 (1H, multiplet) 5.45 (1H, multiplet) 5.62 (1H, doublet) 5.91 (1H, singlet) 2 Ultraviolet absorption Spectrum (methanol solution) λ nax (nm): 238.4 3 Infrared absorption spectrum (KBr method) cm -1 :
3450, 1750 4 Mass spectrum m/e: 420 (M + ) 5 Elemental analysis value (%) As C 24 H 36 O 6 Theoretical value C, 68.54; H, 8.63 Experimental value C, 68.33; H, 8.81 (3) Dissolve 100 mg of 6-hydroxy-isoMB-530B lactone in a small amount of acetone, then add an equivalent amount of 0.2N sodium hydroxide aqueous solution,
Stir at room temperature. This solution was then subjected to lyophilization to obtain 106 mg of 6-hydroxy-isoMB-530B carboxylic acid sodium salt. Physical properties of 6-hydroxy-isoMB-530B carboxylic acid sodium salt 1 NMR spectrum 90M in heavy water using DSS as an internal standard
Measured in Hz. (D 2 O, δ: ppm) 3.78 (1H, multiplet) 4.01 (1H, multiplet) 4.13 (1H, multiplet) 5.49 (1H, multiplet) 5.62 (1H, multiplet) 6.02 (1H, wide Singlet) 2 Shiba external absorption spectrum (aqueous solution) λ nx (nm): 238 3 Infrared absorption spectrum (KBr method) cm -1 : 3400
~2900, 1575 4 Elemental analysis value (%) As C 24 H 37 O 7 Na Theoretical value C, 62.59; H, 8.097 Experimental value C, 62.28; H, 8.31 (4) In the treatment of (2) of Production Example 5 After alkylation with diazomethane, it was applied to Microbondapak C 18 and eluted with 53% methanol, and the fraction containing 6-hydroxy-isoMB-530B carboxylic acid methyl ester was separated and collected. This was purified to obtain 170 mg of the target compound. Physical properties of 6-hydroxy-isoMB-530B carboxylic acid methyl ester (1) NMR spectrum Measured at 90MHz in deuterated acetone using TMS as an internal standard. (CD 3 COCD 3 , δ:
ppm) 3.70 (3H, singlet) 4.22 (1H, multiplet) 5.42 (1H, multiplet) 5.57 (1H, multiplet) 5.92 (1H, doublet) 2 Ultraviolet absorption spectrum (methanol solution) λ nax ( nm): 238.4 3 Infrared absorption spectrum (thin film method) cm -1 :
3400, 2960, 1732 4 Elemental analysis value (%) As C 25 H 40 O 7 Theoretical value C, 66.34; H, 8.91 Experimental value C, 66.28; H, 8.99 Carvone having the above formula () or () of the present invention The acid, its pharmacologically acceptable salt, its lower alkyl ester, or its lactone form are active ingredients of a therapeutic agent for hyperlipidemia hyperoxidation. Examples of dosage forms include tablets, capsules, granules,
Oral administration methods include powders, syrups, etc., and parenteral administration methods include subcutaneous injections, intravenous injections, and suppositories. These various preparations are made according to the conventional method, and depending on the purpose, solubilizing agents, suspending agents, excipients, binders, disintegrants, lubricants, and flavoring agents are added to the main drug, which are commonly used in the pharmaceutical field. It can be formulated using known adjuvants. The dosage varies depending on the symptoms, age, body weight, etc., route of use, and number of times of use, but is usually 0.05 to 25 mg/Kg/day for M-4 class compounds for adults, preferably 0.2 to 25 mg/Kg/day.
20mg/Kg/day, M-4' compound, isoM-
0.1 to 4-class compounds and isoM-4′-class compounds
50 mg/Kg/day, preferably 0.5 to 25 mg/Kg/day, and preferably 0.05 to 25 mg/Kg/day for 3-hydroxy-MB-530B and 6-hydroxy-isoMB-530B compounds. is 0.2~20mg/
Kg/day, and for -6methoxy-isoML-236B class compounds, it is 0.05 to 50 mg/Kg/day, preferably 0.5 to 50 mg/Kg/day.
30mg/Kg/day. Larger doses can be administered as needed. Acute toxicity For example, the acute toxicity of M-4 carboxylic acid sodium salt to mice is LD 50 (mg/Kg) of 8000 mg/Kg or more for oral administration and 2000 mg/Kg for intravenous injection.
It was over Kg. Also, LD 50 against rats
(mg/Kg) is 12000mg/Kg or more by oral administration,
The dose was 400 mg/Kg or more when administered intravenously. Next, examples will be shown. Example 1 Two groups of beagles were prepared (one group consisting of 3 males and the other group consisting of 3 females). To these groups, 25 mg/Kg/day of M-4 carboxylic acid sodium salt was orally administered once a day for 5 consecutive weeks. The blood peroxide lipid levels of these beagle dogs before and after administration were measured using microfluorophotometry [Biochem.Med., Vol. 15, pp. 212-216, 1976]
2009]. The results are shown in Table 1.
【表】
数値は平均値±標準偏差を示す。
試験結果から明らかの通り、投与前を基準とし
て雄性で31.7%、雌性で22.2%の血中過酸化脂質
値の低下が認められた。
実施例 2
M−4′カルボン酸ナトリウム塩を用いて、実施
例1と同様に試験した結果、平均22.3%の血中過
酸化脂質値の低下が認められた。
実施例 3
イソM−4′カルボン酸ナトリウム塩を用いて実
施例1と同様に試験した結果、平均20.0%の血中
過酸化脂質値の低下が認められた。
イソM−4ラクトン体、6−メトキシ−イソ
ML−236Bラクトン体、3−ヒドロキシ−MB−
530Bナトリウム塩及び6−ヒドロキシ−イソ
MB−530Bナトリウム塩についても上記と同様
の試験において、高血清過酸化脂質血症治療効果
が認められた。
前記式()または()を有する化合物およ
びその誘導体は公知の製剤方法により任意の剤
型,例えば錠剤,カプセル剤,散剤,顆粒剤,注
射剤,坐剤,懸濁化剤などとして使用することが
できる。これらの各種製剤は常法に従つて、固体
または液体の担体、稀釈剤,緩衝剤,賦形剤など
製剤技術分野において通常使用され得る既知の補
助剤を用いて製剤化することができる。
製剤例 1(カプセル剤)
M−4カルボン酸ナトリウム塩 10.0mg
乳糖 151.2
トウモロコシデンプン 37.8
ステアリン酸マグネシウム 1.0
200mg
上記処方の粉末を混合し、60メツシユのふるい
を通した後、この粉末200mgを3号ゼラチンカプ
セルに入れカプセル剤とした。
製剤例2 (錠剤)
M−4カルボン酸ナトリウム塩 5.0mg
乳糖 77.4
トウモロコシデンプン 13.0
ステアリン酸マグネシウム 0.6
L−HPC(信越化学工業(株)製品) 24.0
120mg
上記処方のものを通常の製剤操作により、1錠
120mgの錠剤とした。[Table] Values indicate mean ± standard deviation.
As is clear from the test results, blood lipid peroxide levels were reduced by 31.7% in males and 22.2% in females compared to before administration. Example 2 As a result of testing in the same manner as in Example 1 using M-4'carboxylic acid sodium salt, an average reduction of 22.3% in blood lipid peroxide levels was observed. Example 3 As a result of the same test as in Example 1 using isoM-4'carboxylic acid sodium salt, an average decrease of 20.0% in blood lipid peroxide levels was observed. IsoM-4 lactone, 6-methoxy-iso
ML-236B lactone, 3-hydroxy-MB-
530B sodium salt and 6-hydroxy-iso
In a test similar to the above, MB-530B sodium salt was also found to be effective in treating hyperlipidemia peroxidation. The compound having the above formula () or () and its derivatives can be used in any dosage form, such as tablets, capsules, powders, granules, injections, suppositories, suspensions, etc., by known formulation methods. Can be done. These various preparations can be formulated according to conventional methods using known adjuvants that can be commonly used in the field of pharmaceutical preparation, such as solid or liquid carriers, diluents, buffers, and excipients. Formulation Example 1 (Capsule) M-4 carboxylic acid sodium salt 10.0 mg Lactose 151.2 Corn starch 37.8 Magnesium stearate 1.0 200 mg After mixing the powder of the above formulation and passing it through a 60-mesh sieve, 200 mg of this powder was mixed with No. 3 gelatin. It was put into capsules and made into capsules. Formulation Example 2 (Tablets) M-4 carboxylic acid sodium salt 5.0mg Lactose 77.4 Corn starch 13.0 Magnesium stearate 0.6 L-HPC (Shin-Etsu Chemical Co., Ltd. product) 24.0 120mg The above formulation was prepared by normal formulation operations. lock
It was made into a 120mg tablet.
第1図はイソM−4′ラクトン体の磁気共鳴スペ
クトルを示し、第2図は同物質の赤外部吸収スペ
クトルを示す。第3図はイソM−4′カルボン酸メ
チルエステルの核磁気共鳴スペクトルを示し、第
4図は同物質の赤外部吸収スペクトルを示す。
Figure 1 shows the magnetic resonance spectrum of the isoM-4' lactone, and Figure 2 shows the infrared absorption spectrum of the same substance. FIG. 3 shows the nuclear magnetic resonance spectrum of isoM-4'carboxylic acid methyl ester, and FIG. 4 shows the infrared absorption spectrum of the same substance.
Claims (1)
R2は水素原子またはメチル基を示し、R3は水酸
基またはメトキシ基を示す。)を有するカルボン
酸、その薬理上許容しうる塩、その低級アルキル
エステルまたはそのラクトン体を有効成分とする
高血清過酸化脂質血症治療剤。[Claims] 1 formula or (In the formula, R 1 represents a hydrogen atom or a methyl group,
R 2 represents a hydrogen atom or a methyl group, and R 3 represents a hydroxyl group or a methoxy group. ), a pharmacologically acceptable salt thereof, a lower alkyl ester thereof, or a lactone thereof as an active ingredient.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP15860582A JPS5948418A (en) | 1982-09-10 | 1982-09-10 | Agent for treatment of excessive lipid peroxide in serum |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP15860582A JPS5948418A (en) | 1982-09-10 | 1982-09-10 | Agent for treatment of excessive lipid peroxide in serum |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS5948418A JPS5948418A (en) | 1984-03-19 |
JPH0337526B2 true JPH0337526B2 (en) | 1991-06-05 |
Family
ID=15675348
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP15860582A Granted JPS5948418A (en) | 1982-09-10 | 1982-09-10 | Agent for treatment of excessive lipid peroxide in serum |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS5948418A (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5049696A (en) * | 1988-04-11 | 1991-09-17 | Merck & Co., Inc. | Antihypercholesterolemic compounds |
US4916239A (en) * | 1988-07-19 | 1990-04-10 | Merck & Co., Inc. | Process for the lactonization of mevinic acids and analogs thereof |
US5110825A (en) * | 1989-12-28 | 1992-05-05 | Shionogi & Co., Ltd. | Benzofuran derivative |
US9486503B2 (en) | 2012-10-04 | 2016-11-08 | Shionogi & Co., Ltd. | Medicinal agent for suppressing malignant tumor metastasis |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS645571A (en) * | 1987-06-29 | 1989-01-10 | U G Kk | Fire hydrant discharge tester |
-
1982
- 1982-09-10 JP JP15860582A patent/JPS5948418A/en active Granted
Also Published As
Publication number | Publication date |
---|---|
JPS5948418A (en) | 1984-03-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH09508144A (en) | Antifungal sordarin derivative | |
US4083968A (en) | Therapeutic agent for improving cardiovascular function | |
US4164586A (en) | Therapeutic agent for improving cardiovascular function | |
JPH0337526B2 (en) | ||
JPH0136471B2 (en) | ||
US4831053A (en) | Composition for prophylaxis and therapy of hepatitis | |
JPH10287617A (en) | New diterpenes and antivirus agent containing diterpenes as active ingredient | |
JPH0145448B2 (en) | ||
US4560703A (en) | Clavulone derivatives, process for preparing the same, and use of said compounds | |
WO1995032990A1 (en) | Cyclodepsipeptide | |
JP3108474B2 (en) | Active vitamin D derivative | |
JPH0859685A (en) | Phenethyl alcohol glycoside derivative, 5-lipoxygenase inhibitor comprising the same as active ingredient and aldose reductase inhibitor | |
JPS62209070A (en) | Neolignane derivative | |
CN111423451B (en) | 14-hydroxy dihydroartemisinin and derivative, preparation method and application thereof | |
JPH08134002A (en) | Quinone compound | |
JPH0826063B2 (en) | Pomolic acid and oleanolic acid derivatives | |
JPH07206838A (en) | New ascofuranone derivative and blood lipid-lowering agent, hypoglycemic agent, glycation-inhibiting agent and antioxidizing agent containing the same as active ingredient | |
JPH0285211A (en) | Novel phenetyl alcohol glycoside and immune inhibitor | |
JPH05163202A (en) | New polyacetylene compounds and 5-lipoxygenase inhibitor containing polyacetylene compound as active ingredient | |
RU2098422C1 (en) | Pyranone derivative, method of its preparing and pharmaceutical composition | |
JPS62132878A (en) | Novel physiologically active substance monacolin m and production thereof | |
JP4833461B2 (en) | Novel angiogenesis inhibitor | |
JP4452787B2 (en) | New fermentation products | |
JP3524164B2 (en) | Antitumor substance arenastatin A and antitumor agent containing the compound as active ingredient | |
JPH041184A (en) | Cyclohexane derivative |